Rank |
Status |
Study |
1 |
Recruiting
|
Vitamin D in Pediatric Asthma: a Randomized Controlled Open-label Pilot Trial
Conditions: |
Asthma; Vitamin D Deficiency |
Interventions: |
Drug: Vitamin D2 + Vitamin D3; Drug: Vitamin D3 |
Outcome Measures: |
Vitamin D levels; Side Effects Form for Children and Adolescents (SEFCA); Block Kids 2004 Food Frequency Questionnaire; immune status |
|
2 |
Unknown †
|
Vitamin D Replacement After Kidney Transplant
Conditions: |
Kidney Transplantation; Vitamin D Deficiency |
Intervention: |
Dietary Supplement: Vitamin D3 |
Outcome Measures: |
Compare efficacy and safety of two Vitamin D supplements of these doses in normalizing Vitamin D concentrations.; The ability of Vitamin D to reduce parathyroid hormone concentration or change markers of vascular risk, insulin resistance, and/or inflammation, as well as its affect on urine calcium excretion. |
|
3 |
Recruiting
|
Effect of Vitamin D Supplementation on Glucose Tolerance in Subjects at Risk for Diabetes With Low Vitamin D.
Conditions: |
Type 2 Diabetes Mellitus; Vitamin D Deficiency |
Interventions: |
Dietary Supplement: Control; Dietary Supplement: Vitamin D |
Outcome Measures: |
Change in plasma glucose concentration 2 hours after consuming 75g oral glucose (2 hour PC glucose, or 2hrPC glucose); Change in insulin resistance assessed using the homeostasis model assessment of insulin resistance (HOMA-IR); Change in Matsuda insulin sensitivity index; Change in insulin secretion assessed using the homeostasis model assessment of beta-cell function (HOMA-B); Change in insulinogenic index; Change in disposition index derived from HOMA-IR and HOMA-B; Change in disposition index based on oral glucose tolerance test (OGTT); Change in fasting plasma glucose; Change in glucose area under the curve; Change in glycated hemoglobin; Correlation between changes in serum 25-hydroxy-Vitamin D concentration (25(OH)D) and changes in 2 hour PC glucose |
|
4 |
Unknown †
|
Prospective Intervention Study on Vitamin D in Patients With Cystic Fibrosis
Condition: |
Cystic Fibrosis |
Intervention: |
Dietary Supplement: Supplementation with Vitamin D2/D3 |
Outcome Measures: |
Serum 25-hydroxy Vitamin D; Parathyroid hormone (PTH); Inflammatory parameters; Infection parameters; Lung function parameters; Glucose tolerance parameters; Adherence with Vitamin D treatment; Disease-specific quality of life; Plasma calcium; Relative number of patients reaching high abnormal 25(OH)D concentrations; Proportion of patients reaching toxic 25(OH)D concentrations; Proportion of patients with suspect hypercalcaemia symptoms |
|
5 |
Recruiting
|
The Impact of Severe Vitamin D Deficiency and Its Correction on Bone Mineral Density (BMD) in Postmenopausal Women
Condition: |
Vitamin D Deficiency |
Intervention: |
Drug: Vitamin D |
Outcome Measures: |
Change in BMD (Z score) following 10 months of Vitamin D supplementation; To examine the effect of increasing Vitamin D levels on other objective parameters such as PTH, calcium, phosphorus and other subjective parameters such as muscle weakness, according to comparison between baseline visit and end of study visit. |
|
6 |
Recruiting
|
Vitamin B12 Acceptance and Biomarker Response Study
Condition: |
Vitamin B 12 Deficiency |
Interventions: |
Drug: Oral administration of Vitamin B12; Drug: i.m. injection of Vitamin B12 |
Outcome Measures: |
Biochemical response to Vitamin B12 substitution; taking and timing adherence with oral Vitamin B12; Comparison of patient acceptance of oral vs. i.m. Vitamin B12 supplementation |
|
7 |
Recruiting
|
Vitamin D HIV Study
Condition: |
HIV |
Interventions: |
Drug: Vitamin D3; Drug: Placebo |
Outcome Measures: |
Change in Bone Mineral Density (BMD); Areal Change in Bone Mineral Density (aBMD); Volumetric Bone Mineral Density (vBMD); Change in Vitamin D levels; Biochemical markers; Immune function; Muscle measures and frailty; Biochemical Markers |
|
8 |
Recruiting
|
The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List
Conditions: |
Vitamin D Deficiency; Hepatocellular Carcinoma |
Interventions: |
Drug: Vitamin D3 4000 IU; Drug: Vitamin D3 2000 IU |
Outcome Measures: |
Change in serum levels of 25-hydroxyVitamin D; Change in serum levels of liver enzymes (ALT, AST and Alk phos); Change in serum creatinine; Serum Calcium; Change in coagulation profile (PT/PTT and INR); Change in Model for End stage Liver Disease score (MELD) |
|
9 |
Not yet recruiting
|
Effect of Vitamin D Supplementation in Patients With Heart Failure and Vitamin D Deficiency
Conditions: |
Heart Failure; Vitamin D Deficiency |
Interventions: |
Other: Vitamin D Supplementation; Other: Control group (Placebo) |
Outcome Measures: |
Change from baseline in myocardial function and structure at 12 months; Change from baseline in inflammatory cytokines at 12 months; Change from baseline in serum lipid profile at 12 months; Change from baseline in serum calcium at 12 months; Change from baseline in serum parathyroid hormone at 12 months; Change from baseline in serum glucose at 12 months; Change from baseline in serum insulin at 12 months; Change from baseline in 6-minute walk test at 12 months; Change from baseline in serum Vitamin D level at 12 months; Change from baseline in serum natriuretic peptide at 12 months; Change from baseline in systolic blood pressure at 12 months; Change from baseline in diastolic blood pressure at 12 months |
|
10 |
Recruiting
|
The Effect of a High-dose Oral Vitamin D3 Bolus on Serum 25(OH)D3 and Vitamin D Receptor Target Gene Expression
Conditions: |
Vitamin D Receptor Target Gene Expression; Serum 25(OH)D Concentration |
Intervention: |
Dietary Supplement: Vitamin D3 |
Outcome Measures: |
Change from baseline in Vitamin D target gene expression; Change from baseline in serum 25(OH)D |
|
11 |
Recruiting
|
Effect of Vitamin D Treatment on Fatigue
Condition: |
Vitamin D Deficiency |
Interventions: |
Drug: Vitamin D; Other: placebo |
Outcome Measures: |
Intraindividual change of Fatigue as quantified by FAS (δFAS) 30 (±3 days) after administering Vitamin D3 (Cholecalciferol); Efficacy of oral administration of Vitamin D on serum Vitamin D levels (25-Hydroxy-Vitamin D = Cholecalciferol), PTH, Calcium, and Phosphate as compared to placebo. |
|
12 |
Recruiting
|
Vitamin D Replacement in Insulin Resistant South Asians
Conditions: |
Vitamin D Deficiency; Insulin Resistance |
Intervention: |
Drug: Vitamin D3 cholecalciferol |
Outcome Measures: |
HOMA2-IR (homeostatic model assessment of insulin resistance); fasting plasma glucose; HbA1c; two hour plasma glucose; Tolerability of high dose Vitamin D3 treatment regime |
|
13 |
Recruiting
|
Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients
Condition: |
Breast Cancer |
Intervention: |
Drug: calcium and cholecalciferol |
Outcome Measures: |
To evaluate the increase in normalization of serum Vitamin D level; Baseline Vitamin D/calcium status in this patient population; Normalization rate of serum 25-OHD level; Normalization rate of serum 25-OHD level in control patients who shift to experimental strategy; Clinical and biological tolerance profile; Treatment compliance; Quality of life; Impact of study treatments on bone and joint pains induced by aromatase inhibitors; Changes in Vitamin and calcium biological markers; Predictive value of individual biomarkers |
|
14 |
Recruiting
|
Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation
Condition: |
Vitamin D Status During Pregnancy. |
Interventions: |
Drug: Vitamin D3 4000 IU in gummy form; Drug: Placebo gummy Vitamin |
Outcome Measure: |
Maternal and neonatal health status as a function of maternal and infant Vitamin D status |
|
15 |
Unknown †
|
Vitamin D and Glucose Metabolism in Pediatrics
Conditions: |
Insulin Resistance; Obesity; Vitamin D25 Insufficiency |
Interventions: |
Drug: Vitamin D drops; Drug: Placebo drops |
Outcome Measures: |
To determine changes in insulin sensitivity induced by Vitamin D supplementation in obese children with insulin resistance.; To quantify the associations between Vitamin D 25 concentration, insulin resistance, and calcium metabolism in overweight children. |
|
16 |
Not yet recruiting
|
Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5
Condition: |
Vitamin D Deficiency |
Interventions: |
Drug: Vitamin D; Other: Placebo (for Vitamin D) |
Outcome Measures: |
Height at the age of 3 years; Bone densitometry by ultrasound |
|
17 |
Not yet recruiting
|
Vitamin D Treatment in Ulcerative Colitis
Conditions: |
Ulcerative Colitis; Inflammatory Bowel Disease |
Interventions: |
Drug: Vitamin D3; Other: Placebo |
Outcome Measures: |
Mucosal Permeability; Mucosal tight junction protein expression |
|
18 |
Not yet recruiting
|
The Effect of Vitamin D Supplements on Vitamin D Status, Cardiometabolic Health and Immune Defense in Danish Children
Condition: |
Vitamin D Deficiency |
Intervention: |
Dietary Supplement: Vitamin D3 (cholecalciferol) |
Outcome Measures: |
Change in Vitamin D status; Change in anthropometric measurements; Change in body composition; Serum calcium |
|
19 |
Recruiting
|
Optimizing Vitamin D in the Elderly
Condition: |
Deficiency of Vitamin D3 |
Interventions: |
Dietary Supplement: D3 2000 IU/day; Dietary Supplement: D3 4000 IU/day; Dietary Supplement: D3 50,000 IU weekly; Dietary Supplement: Vitamin D3 800 IU/day |
Outcome Measures: |
Total 25-OH Vitamin D3 level; Free 25-OH Vitamin D3 |
|
20 |
Unknown †
|
Efficacy of Vitamin D3 for the Treatment of Psoriatic Patients With Vitamin D Deficiency and Insufficiency
Conditions: |
Psoriasis Vulgaris; Vitamin D Deficiency |
Interventions: |
Dietary Supplement: Vitamin D3; Drug: Placebo |
Outcome Measures: |
Psoriasis Area and Severity Index (PASI Score); Dermatologic Life Qualify Index (DLQI) |
|